Rajesh Agarwal of CD Equisearch is of the view that one should hold Sun Pharma with target of Rs 1150-1200.

Agarwal told CNBC-TV18, "The fundamentals are very strong. The company has reported good numbers. Generic sales have been going up not only EBITDA levels but also even the NPM levels have gone up. One should definitely hold to the counter and with the demerger of the research division and listing of that the company is pure generic company now and one thing there is good prospect going forward. One should definitely hold on to the stock with a target of Rs 1150-1200 in the next six months."